Crohn's Colitis Professional

Impact of Brain-Gut Interactions in the Management of IBD: Findings and Interventions

ReachMD Healthcare Image

This is a module is one of two keynote presentations originally presented during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University: Cutting Edge Approaches to IBD Management on Sept 24, 2022.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    These presentations were recorded during the Crohn’s & Colitis Foundation Central Regional Professional Education Conference at Washington University in St. Louis: Cutting Edge Approaches in IBD Management in 2022 held September 24, 2022, and supported in part by unrestricted educational grants from Boehringer Ingelheim, Bristol Myers Squibb, Ferring Pharmaceuticals, Janssen, and Pfizer, Inc.


  • Learning Objectives

    The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:

    • Discuss studies to identify next generation IBD therapies
    • Analyze the literature of updates in use of anti-tnf and anti-integrin therapies in IBD
    • Describe the mechanism and rationale behind the development of targeted IL 12/23 and IL 23 inhibitors
    • Evaluate current efficacy and safety data for approved IL 23 inhibitors for the management of IBD and Crohn's disease
    • Identify the currently available janus kinase (JAK) inhibitors and S1P modulator for the treatment of moderate to severe ulcerative colitis
    • Implement the safety monitoring required prior to and during treatment with JAK inhibitors and S1P modulators
  • Target Audience

    This activity is designed for physicians and nurses to give updates and updated approaches to treatment of patients with inflammatory bowel diseases. This activity may also be of interest to nutritionists or anyone who specializes in gastroenterology, internal medicine, or surgery. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Crohn’s & Colitis Foundation and Washington University School of Medicine in St. Louis. Washington University School of Medicine in St Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credits Available for this Activity:

    American Medical Association (AMA Credit)
    Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Nurses Credentialing Center (ANCC Credit)
    Washington University School of Medicine in St. Louis designates this enduring material for a maximum of 0.5 ANCC contact hour. 

    Interprofessional Continuing Education (IPCE)
    This activity was planned by and for the healthcare team, and learners will receive a maximum of 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Crohn's Colitis Professional…
but how about a more personalized experience?

Register for free